

22-Apr-20

Dr. Aflah Roohullah
Sydney Southwest Private Hospital
Ingham Institute
Liverpool NSW 2170

Dear Dr. Roohullah,

Re: Application No: 2019-11-968

Study Title: Phase Ib/II Study of Intra-Arterial Liver Isolation Chemotherapy in Patients with Hepatic Metastases from Colorectal Cancer Short Title: SYS-CAPLIOX

Application Type: NEW

Type of Review: FULLBOARD

Name of the Documents Submitted & Approved: Attachments

Medical Physicist's Report

AV-LIVPIBII-02 V3.0 Investigators Brochure

AVAS-IFU rev7 Instructions For Use

AVAS-LEAFLET rev6 Information Leaflet

Oxaliplatin PI

Capecitabine PI

CLEAN- AV-LIVPIBII-01 V4.0_16MAR2020_Clinical Investigation Plan

PI Protocol Signature Page_v4.0_16Mar2020

CLEAN_Patient Information Brochure_V1.0_12Feb2020

Emergency Contact Card_V1.0_29JAN2020

CLEAN - Patient Information Consent Form V3.0_17Mar2020

CLEAN_Short Summary Patient Information and Consent Form V1.0_30Mar2020

CRF - Quality of Life Survey

Includes:

- HREA
- CTN Approval
- 200227-TrialSpecific COC-31Oct2019 - 31Oct2020

Please submit an amendment to advise the committee your plans for commencing and conducting this trial given the current public health considerations relating to the COVID-19 pandemic.

Date of Meeting: 04-Dec-19

Date of Approval: 21-Apr-20

Period of Approval: 21-Apr-20 - 20-Apr-30

Thank you for submitting the above mentioned application.

The Bellberry Human Research Ethics Committee (HREC) reviewed this study in accordance with the National Health and Medical Research Council's National Statement on Ethical Conduct in Human Research (2007, incorporating all updates as at 2018) (National



Statement) on the above meeting date.

This Bellberry HREC is constituted and operates in accordance with the National Statement.

I wish to advise that the Bellberry Human Research Ethics Committee has approved this project and that the application meets the requirements of the National Statement subject to the conditions mentioned below.

CONDITIONS:-

- **THAT YOU ACKNOWLEDGE YOUR AGREEMENT TO THE UNDER MENTIONED CONDITIONS BY SIGNING AND RETURNING A COPY OF THIS LETTER, PRIOR TO THE COMMENCEMENT OF THE RESEARCH. THE SIGNED LETTER CAN BE EMAILED TO BELLBERRY@BELLBERRY.COM.AU OR POSTED TO THE ABOVE ADDRESS.**
- The data collected for the purpose of this research project cannot be used for any other purpose without the approval of the Bellberry Human Research Ethics Committee. Requests to use this data for other purposes must be made in the form of a formal research proposal.
- All research data, including electronic data is to be stored by the Principal Investigator for 15 years after the research has been completed or after the last contact, whichever is the later. Data must be recorded in a durable and appropriately referenced form and comply with relevant privacy protocols.
- That copies of all completed consent forms and any other data used in this research may be inspected at any time by representatives of the Bellberry Human Research Ethics Committee.
- That a report on the progress of the research will be made to the Bellberry Human Research Ethics Committee on **21-Apr-21** or on completion of the trial (if sooner) and then annually for the duration of the trial. This report is to indicate whether any ethical problems or complications have arisen, particularly side effects of drugs used or any other factor which may result in the investigation not producing any result as distinct from the anticipated result.
- That you will notify the Bellberry Human Research Ethics Committee of any changes that may be required within the research proposal.
- Bellberry Human Research Ethics Committee approval is conditional upon your meeting any statutory obligations that you may have in relation to this project.
- Adverse Event reporting should be reported to the Bellberry Human Research Ethics Committee as per the monitoring guidelines posted on the website www.bellberry.com.au.
- Any extension to the initial approval period is to be requested in an application via the eProtocol system together with the inclusion of a progress report.
- That you will provide a copy of the Sponsor's final report when this becomes available.

Details of Ethics Committee:

It is the process of the Bellberry Human Research Ethics Committee not to disclose personal details of its reviewing members. This Project was considered by a Committee that fulfilled the requirements of the National Statement (2007) section 5.1.29 & 5.1.30. A member listing is available as an attachment in eProtocol. Please note that the Principal Investigator and Co-Investigators are not members of the Bellberry Human Research Ethics Committees and were not involved in the review of this study.

This study has been given the above reference number. Please remember to log on to eProtocol for all further correspondence with the Committee.

Please do not hesitate to contact me if further clarification is required.

Yours sincerely



Bellberry Limited
supporting research and ethics

James Toouli

Chair, Committee B (NHMRC HREC Code EC00419)

BELLBERRY HUMAN RESEARCH ETHICS COMMITTEE

PRINCIPAL INVESTIGATOR SIGNATURE DATE

e-protocol